Flinton Capital Management LLC boosted its stake in shares of Chemed Corp. (NYSE:CHE) by 51.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,652 shares of the company’s stock after acquiring an additional 560 shares during the period. Flinton Capital Management LLC’s holdings in Chemed Corp. were worth $338,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Acrospire Investment Management LLC bought a new position in Chemed Corp. during the 2nd quarter worth $120,000. Pacad Investment Ltd. boosted its holdings in shares of Chemed Corp. by 250.0% in the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock valued at $143,000 after purchasing an additional 500 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Chemed Corp. by 12.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after purchasing an additional 83 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Chemed Corp. in the 2nd quarter valued at $209,000. Finally, World Asset Management Inc acquired a new stake in shares of Chemed Corp. in the 2nd quarter valued at $216,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.
In related news, insider Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $197.46, for a total transaction of $197,460.00. Following the completion of the sale, the insider now owns 37,809 shares of the company’s stock, valued at $7,465,765.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick P. Grace sold 500 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $201.48, for a total transaction of $100,740.00. Following the sale, the director now directly owns 4,515 shares of the company’s stock, valued at approximately $909,682.20. The disclosure for this sale can be found here. Insiders sold 16,500 shares of company stock valued at $3,315,600 over the last 90 days. 5.32% of the stock is currently owned by company insiders.
Chemed Corp. (NYSE:CHE) opened at 203.10 on Thursday. The stock has a 50 day moving average price of $195.97 and a 200 day moving average price of $197.73. The company has a market capitalization of $3.25 billion, a price-to-earnings ratio of 50.38 and a beta of 1.13. Chemed Corp. has a 52-week low of $132.92 and a 52-week high of $216.01.
Chemed Corp. (NYSE:CHE) last posted its earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.89 by $0.26. The company had revenue of $415.06 million during the quarter, compared to analyst estimates of $407.56 million. Chemed Corp. had a net margin of 4.16% and a return on equity of 26.18%. Chemed Corp.’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.80 earnings per share. Equities research analysts forecast that Chemed Corp. will post $8.21 earnings per share for the current year.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
What are top analysts saying about Chemed Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemed Corp. and related companies.